Statistics for TG Therapeutics (id:5247 TGTX)

Valuation metrics

Market cap

5.33B

Enterprise value

4.88B

Trailing P/E (ttm)

39.56

Forward P/E

35.32

PEG ratio

35.32

Price/Sales (ttm)

20.14

Price/Book (mrq)

25.61

Enterprise Value/Revenue

18.43

Enterprise Value/EBITDA

-11,961.96

Overview

Shares outstanding

155.66M

Float

133.56M

Shares short

32.00M

% Held by insiders

0.10%

% Held by institutions

0.66%

Average volume (10 days)

4.57M

Average volume (90 days)

Price summary

52-Week low

12.32

52-Week high

36.84

52-Week change

63.14%

Beta

2.19

50-Day moving average

25.81

200-Day moving average

19.82

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

April 30th, 2012

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-5.42%

Operating margin

14.82%

Operational effectiveness

Return on assets

-0.07%

Return on equity

-8.05%

Income statement

Revenue (ttm)

1.83

Revenue per share (ttm)

1.83

Quarterly revenue growth (yoy)

-0.97

Gross profit (ttm)

219.53M

EBITDA

26.10M

Net income to common (ttm)

-14,364,000.00

Diluted EPS (ttm)

-0.10

Quarterly earnings growth (yoy)

-96.60%

Balance sheet

Total cash (mrq)

341.04M

Total cash per share (mrq)

2.38

Total debt (mrq)

254.32M

Total Debt/Equity (mrq)

132.35

Current ratio (mrq)

458.80%

Book value per share (mrq)

1.34

Cash flow

Cash flow statement

-28,086,000.00

Levered free cash flow (LFCF)

-45,570,376.00